Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2021

Hamada Akira, Suda Kenichi, Koga Takamasa, Fujino Toshio, Nishino Masaya, Ohara Shuta, Chiba Masato, Shimoji Masaki, Takemoto Toshiki, Soh Junichi, Uchida Tetsuro, Mitsudomi Tetsuya

Abstract excerpt

OBJECTIVES: The LUX-Lung 8 randomized trial (LL8) demonstrated a prolonged progression-free survival (PFS) in patients with metastatic squamous cell carcinoma (SCC) of the lung after treatment with afatinib compared with erlotinib. A secondary analysis of the LL8 reported that the presence of rare HER2/HER4 mutations may be partly responsible for this result. Patients with HER2 (hazard ratio [HR] 0.06/p-value...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 34741886
DOI: 10.1016/j.lungcan.2021.10.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.PMID 34741886Read ↗

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.Semantic proximity Read ↗

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.Semantic proximity Read ↗

Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary AdenocarcinomaSemantic proximity Read ↗

LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.Semantic proximity Read ↗

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.Semantic proximity Read ↗

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.Semantic proximity Read ↗

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Semantic proximity Read ↗

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.Semantic proximity Read ↗

Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272Semantic proximity Read ↗

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.Semantic proximity Read ↗

Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.Semantic proximity Read ↗

HER-3 Expression and MEK Activation in Non-small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.